Docoh
Loading...

IPSC Century Therapeutics

News

From Benzinga Pro
60 Biggest Movers From Yesterday
11 Jan 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday.
45 Stocks Moving In Monday's Mid-Day Session
10 Jan 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88.
12 Health Care Stocks Moving In Monday's Pre-Market Session
10 Jan 22
Pre-Market Outlook, Markets, Movers
Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies
10 Jan 22
Biotech, News, Health Care, Contracts, Small Cap, Movers, Trading Ideas, General
Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a
Century Therapeutics And Bristol Myers Squibb Enter Into A Strategic Collaboration To Develop iPSC-derived Allogeneic Cell Therapies
10 Jan 22
Biotech, News, Contracts, General
Collaboration brings together Century’s industry leading iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development First two programs
Stocks That Hit 52-Week Lows On Thursday
6 Jan 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 615 stocks hit new 52-week lows.
51 Biggest Movers From Yesterday
28 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Microbot Medical Inc. (NASDAQ: MBOT) shares climbed 65.1% to close at $8.95 on Monday after the company announced a strategic collaboration with Stryker Corporation to develop the LIBERTY robotic system for neurovascular applications.
SVB Leerink Maintains Outperform on Century Therapeutics, Lowers Price Target to $32
19 Nov 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Daina Graybosch maintains Century Therapeutics (NASDAQ:IPSC) with a Outperform and lowers the price target from $33 to $32.

Press releases

From Benzinga Pro
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
10 Jan 22
Press Releases
Collaboration brings together Century's industry leading iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb's expertise in cell therapy and oncology drug development First two programs include a
Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
4 Jan 22
News, Press Releases
PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today
Century Therapeutics Added to the NASDAQ Biotechnology Index
17 Dec 21
Press Releases
PHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today
Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Provides Pipeline Updates
16 Dec 21
News, Health Care, Analyst Ratings, Press Releases
- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 - - Company announces plans for Phase 1 ELiPSE-1 trial of CNTY-101 in
Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
10 Nov 21
Earnings, Press Releases
Lead program, CNTY-101 in relapsed/refractory non-Hodgkin's lymphoma, remains on track for IND filing in mid-2022 Pre-clinical data from CNTY-101 program and CAR-iT platform to be presented at the ASH Annual Meeting